RNAC — Cartesian Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $163.83m
- $38.69m
- $2.80m
Annual cashflow statement for Cartesian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -25.7 | 35.4 | -220 | -77.4 | -130 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 12.2 | -7.92 | 182 | 58.1 | 70.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -48.2 | -60.4 | 4.97 | -5.79 | -8.06 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -60.4 | -31.6 | -51.2 | -23.7 | -73.9 |
| Capital Expenditures | -1.08 | -1.2 | -0.206 | -9.09 | -5.45 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -16.1 | -13.8 | 34.8 | 0.351 | 0 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -17.1 | -15 | 34.6 | -8.74 | -5.45 |
| Financing Cash Flow Items | 0 | -0.11 | 0 | -0.066 | -8.38 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 52.9 | 39.2 | -13.1 | 168 | -8.05 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -24.6 | -7.4 | -29.8 | 136 | -87.4 |